JP2017527274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527274A5 JP2017527274A5 JP2017504103A JP2017504103A JP2017527274A5 JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5 JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- seq
- sequence
- bispecific binding
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029342P | 2014-07-25 | 2014-07-25 | |
| US62/029,342 | 2014-07-25 | ||
| PCT/US2015/041989 WO2016014942A1 (en) | 2014-07-25 | 2015-07-24 | Bispecific her2 and cd3 binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527274A JP2017527274A (ja) | 2017-09-21 |
| JP2017527274A5 true JP2017527274A5 (https=) | 2018-10-18 |
| JP6871155B2 JP6871155B2 (ja) | 2021-05-12 |
Family
ID=53836217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504103A Active JP6871155B2 (ja) | 2014-07-25 | 2015-07-24 | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10519248B2 (https=) |
| EP (1) | EP3172236B1 (https=) |
| JP (1) | JP6871155B2 (https=) |
| KR (1) | KR102638104B1 (https=) |
| CN (1) | CN107124884B (https=) |
| AU (1) | AU2015292374B2 (https=) |
| BR (1) | BR112017001513A2 (https=) |
| CA (1) | CA2956014C (https=) |
| ES (1) | ES2832704T3 (https=) |
| IL (1) | IL250249B (https=) |
| MX (1) | MX386342B (https=) |
| RU (1) | RU2017105849A (https=) |
| SG (1) | SG11201700506TA (https=) |
| WO (1) | WO2016014942A1 (https=) |
| ZA (1) | ZA201701341B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| US11820832B2 (en) | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| US10519248B2 (en) | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| US11046768B2 (en) * | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| CA3051484A1 (en) * | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| CN107854490A (zh) * | 2017-09-26 | 2018-03-30 | 首都医科大学附属北京世纪坛医院 | 一种经修饰的t细胞及其应用 |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| CA3093694A1 (en) * | 2018-03-12 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
| US20210008113A1 (en) * | 2018-03-27 | 2021-01-14 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
| CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
| CR20200459A (es) * | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl |
| IL279399B1 (en) * | 2018-06-14 | 2026-04-01 | Bioatla Llc | Multispecific antibody templates |
| CA3118397A1 (en) * | 2018-11-01 | 2020-05-07 | Shandong Newtime Pharmaceutical Co., Ltd. | Bispecific antibody targeting cd3 and bcma, and uses thereof |
| CN111196856A (zh) * | 2018-11-19 | 2020-05-26 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体 |
| WO2020113164A1 (en) * | 2018-11-30 | 2020-06-04 | Memorial Sloan Kettering Cancer Center | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
| WO2020123642A1 (en) * | 2018-12-11 | 2020-06-18 | The Translational Genomics Research Institute | Identification of her2 mutations in lung cancer and methods of treatment |
| AU2020225631A1 (en) | 2019-02-22 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| CN113874399B (zh) * | 2019-05-23 | 2025-07-11 | 维洛斯生物股份有限公司 | 抗ror1/抗cd3双特异性结合分子 |
| CN114401744B (zh) * | 2019-06-26 | 2024-11-05 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| EP4126954A4 (en) * | 2020-03-23 | 2024-08-21 | Cytoarm Co. Ltd. | BISPECIFIC ANTIBODIES FOR USE IN THE PRODUCTION OF ARMED IMMUNE CELLS |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US20230270857A1 (en) * | 2020-07-28 | 2023-08-31 | Memorial Sloan Kettering Cancer Center | Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof |
| US20230374150A1 (en) * | 2020-10-12 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023014810A2 (en) * | 2021-08-04 | 2023-02-09 | Abpro Corporation | Anti-her2 antibodies and uses thereof |
| US20240415888A1 (en) * | 2021-10-20 | 2024-12-19 | Memorial Sloan Kettering Cancer Center | Anti-tshr multi-specific antibodies and uses thereof |
| KR102803655B1 (ko) | 2021-12-29 | 2025-05-08 | 건국대학교 글로컬산학협력단 | 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| KR102857671B1 (ko) | 2021-12-29 | 2025-09-10 | 건국대학교 글로컬산학협력단 | 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| EP4658326A2 (en) * | 2023-02-04 | 2025-12-10 | Imagion Biosystems, Inc. | Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging |
| WO2025076473A1 (en) * | 2023-10-06 | 2025-04-10 | Fred Hutchinson Cancer Center | Proteins bispecific to cd3 and nkg2dl and associated uses thereof |
| WO2025085781A1 (en) | 2023-10-19 | 2025-04-24 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| WO2010099536A2 (en) | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Engineered proteins with high affinity for dota chelates |
| CN114805583A (zh) * | 2010-05-27 | 2022-07-29 | 根马布股份公司 | 针对her2的单克隆抗体 |
| DK3323830T3 (da) * | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| HUE045348T2 (hu) * | 2011-05-08 | 2019-12-30 | Legochem Biosciences Inc | Fehérje-hatóanyag konjugátumok és eljárás elõállításukra |
| EP2723380B1 (en) * | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| EP2748340B1 (en) * | 2011-11-02 | 2016-06-01 | Ajinomoto Co., Inc. | Method for secretory production of proteins |
| EP2895203A4 (en) * | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| CN104271602B (zh) * | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| US10519248B2 (en) | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| CA2976074A1 (en) | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| CA3051484A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
-
2015
- 2015-07-24 US US15/328,288 patent/US10519248B2/en active Active
- 2015-07-24 SG SG11201700506TA patent/SG11201700506TA/en unknown
- 2015-07-24 WO PCT/US2015/041989 patent/WO2016014942A1/en not_active Ceased
- 2015-07-24 AU AU2015292374A patent/AU2015292374B2/en active Active
- 2015-07-24 BR BR112017001513-7A patent/BR112017001513A2/pt not_active Application Discontinuation
- 2015-07-24 KR KR1020177004024A patent/KR102638104B1/ko active Active
- 2015-07-24 JP JP2017504103A patent/JP6871155B2/ja active Active
- 2015-07-24 CN CN201580051950.XA patent/CN107124884B/zh active Active
- 2015-07-24 RU RU2017105849A patent/RU2017105849A/ru not_active Application Discontinuation
- 2015-07-24 CA CA2956014A patent/CA2956014C/en active Active
- 2015-07-24 ES ES15750184T patent/ES2832704T3/es active Active
- 2015-07-24 MX MX2017001031A patent/MX386342B/es unknown
- 2015-07-24 EP EP15750184.2A patent/EP3172236B1/en active Active
-
2017
- 2017-01-23 IL IL250249A patent/IL250249B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01341A patent/ZA201701341B/en unknown
-
2019
- 2019-12-13 US US16/714,636 patent/US11987642B2/en active Active
-
2025
- 2025-02-10 US US19/049,937 patent/US20260071005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527274A5 (https=) | ||
| RU2017105849A (ru) | Биспецифические молекулы, связывающие her2 и cd3 | |
| JP2020063262A5 (https=) | ||
| Marvin et al. | Recombinant approaches to IgG‐like bispecific antibodies | |
| JP2017520575A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020501531A5 (https=) | ||
| JP2018503380A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| WO2013044215A4 (en) | Vegf/dll4 binding agents and uses thereof | |
| RU2016151645A (ru) | Биспецифические гетеродимерные диантитела и их применение | |
| JP2019500011A5 (https=) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| IL295295A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| JP2021515798A5 (https=) | ||
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| JP2021522347A5 (https=) |